Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 guselkumab study in pediatric moderately to severely active ulcerative colitis
jRCT2071230116Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of guselkumab in autoimmune colitis, sponsored by Janssen Pharmaceutical. Primary endpoint: Clinical remission at Week 56. Started Mar 2024; status: recruiting.
02
Drugs
guselkumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2071230116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230116.